NL-OMON33851已完成不适用
Imaging the effect of HSP90 inhibitor AUY922 on HER2 expression by means of 89Zr-trastuzumab PET. A side study to the phase I-II study with AUY922 in either HER2 or ER positive locally advanced or metastatic breast cancer: protocol CAUY922A2101. - 89Zr-trastuzumab PET for imaging the effect of HSP90 inhibition
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational non invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- patients with HER2 positive, trastuzumab (and lapatinib) refractory breast cancer
- •- participation in the phase I-II trial with HSP90 inhibitor AUY922 (in- and exclusion criteriafor this study with AUY922 are described in protocol CAUY922A2101 -METc 2008.237- section 5.1 and 5.2 (p 37-40).
排除标准
- •- no participation in the phase I-II trial with HSP90 inhibitor AUY922
研究者
相似试验
已完成
不适用
Imaging the effect of HSP90 inhibitor AUY922 on VEGF by means of 89Zr-bevacizumab PET. A side study to the phase I-II study with AUY922 in adult patients with advanced solid malignancies, or either HER2 or ER positive locally advanced or metastatic breast cancer: protocol CAUY922A2101.mammary carcinoma1000629110006232breast cancerNL-OMON33855niversitair Medisch Centrum Groningen11
已完成
不适用
89Zr-trastuzumab PET for Imaging the Effect of HSP90 InhibitionBreast CancerNCT01081600University Medical Center Groningen7
进行中（未招募）
1 期
A clinical trial to investigate the safety and effect of a drug called AT13387 on its own or given with another drug Abiraterone Acetate on certain types of Prostate Cancer that does not respond to treatment with Abiraterone alone.Castration-Resistant Prostate Cancer (CRPC)MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001574-28-GBAstex Pharmaceuticals Inc49
进行中（未招募）
不适用
A clinical trial to investigate the safety and effect of a drug called AT13387 on its own or given with another drug Abiraterone Acetate on certain types of Prostate Cancer that does not respond to treatment with Abiraterone alone.Castration-Resistant Prostate Cancer (CRPC)MedDRA version: 14.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001574-28-ESAstex Pharmaceuticals Inc164
进行中（未招募）
1 期
A study to test a new product AT13387 in lung cancer.on-small cell lung cancer (NSCLC) which represents 85% of all lung cancers.MedDRA version: 17.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001575-37-ESAstex Pharmaceuticals, Inc.220